 For an undisclosed amount, Harrow Health Inc NASDAQ: HROW has agreed to acquire MAQ-100 U.S. and Canadian commercial rights from Wakamoto Pharmaceutical Co Ltd. MAQ-100 is a preservative-free triamcinolone acetonide ophthalmic injection. 